Sandoz : EMA Accepts MAA For Proposed Biosimilar Denosumab
(RTTNews) – Sandoz, a Novartis (NVS) division engaged in generic pharmaceuticals and biosimilars, said Thursday that the European Medicines Agency has accepted the marketing authorization applications for proposed biosimilar denosumab for regulatory review.